Obesity and Alzheimer’s drugs pack one-two punch to lift Eli Lilly
Investor optimism for Eli Lilly ‘s diabetes and obesity treatments in 2023 lifted the stock to its seventh annual gain in a row. In the new year, it should be …
stock takes
Wall Street analysts name 13 of our stocks as top picks for 2024
This year’s powerful rally has more than made up for the carnage of 2022 on Wall Street. Tech stocks reasserted their leadership and even some out-of-favor sectors perked up in …
2 reasons to like the stock
Morgan Stanley outgoing CEO James Gorman on Thursday highlighted why we’re staying in the bank stock. During his CNBC exit interview , Gorman forecasted a better environment for Morgan Stanley’s …
Starbucks faces protests, union strife and China headwinds
Starbucks is facing multiple challenges in major markets both internationally and in the U.S., making shareholders like us wonder if it’s a good idea to sell shares before the company’s …
New data on Eli Lilly’s weight-loss drug shows its outlook is bright
The launch of Eli Lilly ‘s weight-loss drug Zepbound — a key pillar of our investment thesis in the pharmaceuticals giant — is going swimmingly in the U.S., Jefferies said …
Here’s what’s driving Wall Street’s newfound bullishness on Coterra
Wall Street analysts are warming up to Coterra Energy , a stock we bought more shares of just last week when it was firmly out of favor. In recent days, …
Broadcom, Apple and Microsoft get positive nods on Wall Street
Tech stocks have soared this year, with chip designer Broadcom nearly doubling year to date, and iPhone maker Apple and software and cloud giant Microsoft soaring more than 50% each. …
Flying solo without Cigna will keep Humana focused on 2 big priorities in 2024
It looks like Cigna has scrapped its takeover bid for Club holding Humana , removing a dark cloud over both stocks that’s lingered since the acquisition talks surfaced nearly two …
Weight gain after stopping Eli Lilly’s new obesity treatment should help, not hurt the stock
Some Eli Lilly investors appear concerned about clinical trial data that showed patients regained weight after they stopped taking the company’s obesity drug Zepbound. The situation seems rather clear-cut to …
Why Ford should double down on hybrids as it backs off EVs
Ford Motor ‘s decision to cut production of its electric pick-up allows the automaker to refocus its strategy around its highly profitable hybrid vehicles, which in turn should boost its …